Pfizer (NYSE: PFE) is expected to report Q4 earnings on Jan. 29. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Pfizer's revenues will compress -14.1% and EPS will wither -12.0%.

The average estimate for revenue is $14.38 billion. On the bottom line, the average EPS estimate is $0.44.

Revenue details
Last quarter, Pfizer recorded revenue of $13.98 billion. GAAP reported sales were 16% lower than the prior-year quarter's $16.61 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $0.53. GAAP EPS of $0.43 for Q3 were 10% lower than the prior-year quarter's $0.48 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 81.6%, 170 basis points better than the prior-year quarter. Operating margin was 31.8%, 100 basis points worse than the prior-year quarter. Net margin was 23.0%, 50 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $58.43 billion. The average EPS estimate is $2.17.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 5,460 members out of 6,050 rating the stock outperform, and 590 members rating it underperform. Among 1,583 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 1,484 give Pfizer a green thumbs-up, and 99 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pfizer is outperform, with an average price target of $26.82.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Pfizer. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.